Lucid’s LucidDx Labs signs deal with MediNcrease

By LabPulse.com staff writers

May 9, 2022 -- Pavmed subsidiary Lucid Diagnostics announced that its laboratory LucidDx Labs has signed a deal to supply its EsoGuard DNA test to members of MediNcrease Health Plans.

This is Lucid's first agreement with a commercial payer. The deal will provide in-network access and payment for Lucid's EsoGuard DNA test to those insured by MediNcrease. The health insurance plan currently provides coverage to 8 million people.

The EsoGuard test is a tool that helps prevent esophageal cancer deaths through the early detection of esophageal precancer in at-risk chronic heartburn patients.

Lucid promotes new guideline from ACG on esophageal cancer
Diagnostics developer Lucid Diagnostics is highlighting updated clinical guidelines for esophageal cancer screening from the American College of Gastroenterology...
1st patient enrolled in study for Lucid's EsoGaurd test
Lucid Diagnostics said the first patient has been enrolled in a study of the company's EsoGuard Esophageal DNA Test at the Louis Stokes Cleveland Department...
Lucid launches 3 new test centers
Lucid Diagnostics, a Pavmed subsidiary, has launched Lucid Test Centers in Seattle, Portland, and Boise, ID. After physician referrals, patients can get...
Lucid closes Nasdaq initial public offering
The cancer prevention medical diagnostics firm Lucid Diagnostics, a subsidiary of PAVmed, has closed its initial public offering.
Lucid Diagnostics files for IPO on Nasdaq exchange
Lucid Diagnostics has filed for an initial public offering (IPO), and the company's shares will be traded on the Nasdaq stock exchange under the symbol...

Copyright © 2022 LabPulse.com

Last Updated mp 5/9/2022 1:38:46 PM